Clinical application of MRI-guided puncture of breast microlesions / 中华肿瘤杂志

ABSTRACT

<p><b>OBJECTIVE</b>To explore the clinical indications of MRI-guided puncture positioning or biopsy, and evaluate the clinical practical value.</p><p><b>METHODS</b>The clinicopathological data of 30 patients who underwent MRI-guided puncture positioning or biopsy were retrospectively collected and analyzed, and the patients were followed up after operation.</p><p><b>RESULTS</b>The success rate of MRI-guided puncture was 100%. After biopsy or surgical resection, the pathological diagnoses were as follows 6 cases (20.0%) of invasive carcinoma, 9 cases (30.0%) of ductal carcinoma in suit (DCIS), and 15 cases (50.0%) of benign lesions, and the false negative rate was 0.In the 30 patients, the lesions of 22 patients were not clear and difficult to analyze qualitatively by ultrasound or mammography imaging examination. After MRI-guided puncture positioning or biopsy, the pathological examination showed that 11 cases (50.0%) of them were malignant tumors. MRI examinations indicated as malignant in 21 cases, among them, seven cases were pathologically confirmed as benign pathology, with a false positive rate of 33.3%. MRI examination considered benign in 9 cases, in which one case was pathologically diagnosed as malignant, thus, the false negative rate was 11.1%.In the 30 patients, there were no hematoma, infection and other complications after the puncture. The median follow-up time was 7.5 months. One patient died due to breast cancer metastasis, one patient showed relapse by imaging examination and underwent surgery, one case was lost, and the remaining patients were normal in the regularly follow-up results.</p><p><b>CONCLUSIONS</b>MRI-guided biopsy of breast microlesions is a safe, rapid and accurate diagnostic method. When the ultrasound and mammography can not find clear lesions or the lesions are difficult to analyze qualitatively, MRI-guided puncture positioning or biopsy can be applied to improve early diagnosis and treatment, and reduce false negative rate of breast cancer.</p>